| Authors: |
Aamdal E; Department of Oncology, Oslo University Hospital, Oslo, Norway.; Institute of Clinical Medicine, Faculty of Medicine, University of Oslo, Oslo, Norway.; Department of Oncology, Akershus University Hospital, Lørenskog, Norway., Inderberg EM; Department of Cellular Therapy, Oslo University Hospital, Oslo, Norway., Ellingsen EB; Institute of Clinical Medicine, Faculty of Medicine, University of Oslo, Oslo, Norway.; Department of Tumor Biology, Institute for Cancer Research, Oslo University Hospital, Oslo, Norway.; Ultimovacs Allmennaksjeselskap (ASA), Oslo, Norway., Rasch W; Ultimovacs Allmennaksjeselskap (ASA), Oslo, Norway., Brunsvig PF; Department of Oncology, Oslo University Hospital, Oslo, Norway., Aamdal S; Department of Oncology, Oslo University Hospital, Oslo, Norway.; Institute of Clinical Medicine, Faculty of Medicine, University of Oslo, Oslo, Norway.; Ultimovacs Allmennaksjeselskap (ASA), Oslo, Norway., Heintz KM; Department of Tumor Biology, Institute for Cancer Research, Oslo University Hospital, Oslo, Norway., Vodák D; Department of Tumor Biology, Institute for Cancer Research, Oslo University Hospital, Oslo, Norway., Nakken S; Department of Tumor Biology, Institute for Cancer Research, Oslo University Hospital, Oslo, Norway.; Centre for Cancer Cell Reprogramming, Institute of Clinical Medicine, Faculty of Medicine, University of Oslo, Oslo, Norway., Hovig E; Department of Tumor Biology, Institute for Cancer Research, Oslo University Hospital, Oslo, Norway.; Center for Bioinformatics, Department of Informatics, University of Oslo, Oslo, Norway., Nyakas M; Department of Oncology, Oslo University Hospital, Oslo, Norway.; Institute of Clinical Medicine, Faculty of Medicine, University of Oslo, Oslo, Norway., Guren TK; Department of Oncology, Oslo University Hospital, Oslo, Norway., Gaudernack G; Institute of Clinical Medicine, Faculty of Medicine, University of Oslo, Oslo, Norway.; Ultimovacs Allmennaksjeselskap (ASA), Oslo, Norway. |
